Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
MorphoSys: Novartis’ Latest Antibody Deal - Exclusive TV Interview




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: MorphoSys: Novartis’ Latest Antibody Deal - Exclusive TV Interview
Released on: December 01, 2007. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Fintan Walton talks to Dr Simon Moroney, Co-Founder and CEO of MorphoSys, in this exclusive TV interview following the company’s US$1 B deal with Novartis on 2 December 2007.
  • Summary
  • Transcript
  • Participants
  • Company
Fintan Walton talks to Dr Simon Moroney, Co-Founder and CEO of MorphoSys, in this exclusive TV interview following the company’s US$1 B deal with Novartis on 2 December 2007. The long-term collaboration agreement is focused on MorphoSys’ HuCAL human antibody technology, and has been hailed as a transforming deal for MorphoSys. Dr Moroney talks about the structure of the agreement and how it affects the company’s existing partnerships. He goes on to discuss MorphoSys’ investment in its own pipeline, and how he sees this advancing the company in the future.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Dr Simon Moroney is one of MorphoSys’s co-founders. He studied chemistry in his native New Zealand, and was a Commonwealth Scholar at the University of Oxford, where he completed a DPhil in Chemistry in 1984. Before co-founding MorphoSys in 1992, Dr Moroney held positions at the University of Cambridge, UK, at the University of British Columbia, Canada, and in the Chemistry Department of the ETH in Zurich, Switzerland. Subsequently he was an Associate at the Harvard Medical School, Boston, Massachusetts, and an employee of ImmunoGen, where he worked on the development of antibody-based cancer drugs. In 2002, Dr Moroney was awarded the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany) for his services to the biotechnology industry.
MorphoSys AG